{"id":200019,"date":"2024-11-23T15:26:16","date_gmt":"2024-11-23T21:26:16","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/11\/lorbrena-effective-as-initial-treatment-of-alk-positive-nsclc"},"modified":"2024-11-23T15:26:16","modified_gmt":"2024-11-23T21:26:16","slug":"lorbrena-effective-as-initial-treatment-of-alk-positive-nsclc","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/11\/lorbrena-effective-as-initial-treatment-of-alk-positive-nsclc","title":{"rendered":"Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/lorbrena-effective-as-initial-treatment-of-alk-positive-nsclc3.jpg\"><\/a><\/p>\n<p>The drug <a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"d156db01-4ae8-4bf0-b2b0-25bf950bd431\" href=\"https:\/\/4g5ku1mlib.execute-api.us-east-1.amazonaws.com:443\/about-cancer\/treatment\/drugs\/lorlatinib\">lorlatinib (Lorbrena)<\/a> is superior to <a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"f2154D80-10bf-4b0c-9d20-cb6120e3353e\" href=\"https:\/\/4g5ku1mlib.execute-api.us-east-1.amazonaws.com:443\/about-cancer\/treatment\/drugs\/crizotinib\">crizotinib (Xalkori)<\/a> as an initial treatment for people with advanced non-small cell lung cancer (NSCLC) that has changes in the <em>ALK<\/em> gene, according to new results from a global clinical trial.<\/p>\n<p>The findings are the latest from the CROWN study. Participants were randomly assigned to receive either lorlatinib or crizotinib as a treatment for advanced lung tumors with <em>ALK<\/em> gene mutations, a disease called ALK-positive lung cancer.<\/p>\n<p>Several years ago, study investigators reported that participants who received lorlatinib went longer without the disease worsening, known as <a class=\"\" data-glossary-id=\"CDR0000044782\" href=\"https:\/\/4g5ku1mlib.execute-api.us-east-1.amazonaws.com:443\/Common\/PopUps\/popDefinition.aspx?id=CDR0000044782&version=Patient&language=en\">progression-free survival<\/a>, than those who received crizotinib.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The drug lorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with advanced non-small cell lung cancer (NSCLC) that has changes in the ALK gene, according to new results from a global clinical trial. The findings are the latest from the CROWN study. Participants were randomly assigned to receive either lorlatinib [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-200019","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/200019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=200019"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/200019\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=200019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=200019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=200019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}